CardioDx Presents Comparative Effectiveness Claims Analysis Highlighting the Clinical Value of the Corus® CAD Precision Medicine Blood Test in Elderly Patients at the Gerontological Society of America 2018 Annual Meeting
December 19, 2018 08:00 ET
|
CardioDx, Inc.
REDWOOD CITY, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, presented results of a comparative effectiveness...
Results of a Comparative Effectiveness Claims Analysis from a Large Commercial Payer, Presented at the AHA Scientific Sessions 2018, Reinforce the Clinical Utility of the Corus® CAD Blood Test in the Outpatient Assessment of Obstructive CAD
December 17, 2018 11:00 ET
|
CardioDx, Inc.
– Patients Who Received the Corus CAD Test Experienced Significantly Lower Rates of Downstream Invasive Coronary Angiography, CAD-Related ER and Doctor Visits, Hospitalizations, and Noninvasive...